Japanese-based Takeda Pharmaceutical Company and Medicines for Malaria Venture in Switzerland (MMV) have signed an agreement to start a new joint research programme aimed at finding lead compounds for malaria treatment.

Takeda and MMV initially announced a screening programme for malaria in 2013 to further advance potential hits identified in the former’s library of proprietary compounds, a process known as Hit-to-Lead research.

The screening programme and the latest agreement are both funded through the Global Health Innovative Technology Fund (GHIT Fund).

Under the agreement, both companies will evaluate the activity of multiple hits and aim to identify potential novel antimalarial leads within one year.

Takeda will provide compounds and scientific expertise, while MMV will provide scientific and malaria expertise.

"Under the agreement, both companies will evaluate the activity of multiple hits and aim to identify potential novel antimalarial leads within one year."

Takeda and MMV’s programmes that are currently active comprise research on proteasome inhibitors as new potent resistance-reversing anti-malarials (Target Research), commercial formulation development of DSM265 (Phase II), and clinical study of DSM421 (Phase I).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In a separate announcement, Takeda said it will work with the Center for iPS Cell Research and Application at Kyoto University (CiRA) and Riken to search for a drug for NGLY1 deficiency.

The genetic rare disorder NGLY1 deficiency is caused by mutations in the NGLY1 gene and is characterised by various symptoms, including developmental and motor disorders, seizure and decreased production of tears.

Takeda has also announced that the Japanese Ministry of Health, Labour and Welfare approved its ninlaro capsules to treat patients with relapsed or refractory multiple myeloma in Japan.

Multiple myeloma is a cancer of the plasma cells, which are found in the bone marrow and can affect many bones in the body, possibly resulting in compression fractures, lytic bone lesions and related pain.